BRPI0812919A2 - Bloqueadores de canal de cálcio de fenilalquilamina de ação curta e uso dos mesmos - Google Patents

Bloqueadores de canal de cálcio de fenilalquilamina de ação curta e uso dos mesmos

Info

Publication number
BRPI0812919A2
BRPI0812919A2 BRPI0812919-3A2A BRPI0812919A BRPI0812919A2 BR PI0812919 A2 BRPI0812919 A2 BR PI0812919A2 BR PI0812919 A BRPI0812919 A BR PI0812919A BR PI0812919 A2 BRPI0812919 A2 BR PI0812919A2
Authority
BR
Brazil
Prior art keywords
lockers
calcium channel
short action
phenylalkylamine calcium
phenylalkylamine
Prior art date
Application number
BRPI0812919-3A2A
Other languages
English (en)
Inventor
Martin P Maguire
Elise Rioux
Harry J Leighton
Original Assignee
Milestone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milestone Pharmaceuticals Inc filed Critical Milestone Pharmaceuticals Inc
Publication of BRPI0812919A2 publication Critical patent/BRPI0812919A2/pt
Publication of BRPI0812919B1 publication Critical patent/BRPI0812919B1/pt
Publication of BRPI0812919B8 publication Critical patent/BRPI0812919B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0812919A 2007-06-20 2008-06-19 composição farmacêutica que compreende um composto e kit BRPI0812919B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93644007P 2007-06-20 2007-06-20
PCT/US2008/007665 WO2008156820A1 (en) 2007-06-20 2008-06-19 Short acting phenylalkylamine calcium channel blockers and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0812919A2 true BRPI0812919A2 (pt) 2014-10-07
BRPI0812919B1 BRPI0812919B1 (pt) 2019-01-29
BRPI0812919B8 BRPI0812919B8 (pt) 2021-05-25

Family

ID=40156562

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812919A BRPI0812919B8 (pt) 2007-06-20 2008-06-19 composição farmacêutica que compreende um composto e kit

Country Status (19)

Country Link
US (16) US20100190852A1 (pt)
EP (1) EP2170050B1 (pt)
JP (1) JP5421908B2 (pt)
KR (1) KR101541557B1 (pt)
CN (1) CN101754678B (pt)
AU (1) AU2008266798B2 (pt)
BR (1) BRPI0812919B8 (pt)
CA (1) CA2693627C (pt)
CY (1) CY1115619T1 (pt)
DK (1) DK2170050T3 (pt)
ES (1) ES2498047T3 (pt)
HK (1) HK1140913A1 (pt)
HR (1) HRP20140801T1 (pt)
MX (1) MX347325B (pt)
NZ (1) NZ582033A (pt)
PL (1) PL2170050T3 (pt)
PT (1) PT2170050E (pt)
SI (1) SI2170050T1 (pt)
WO (1) WO2008156820A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693627C (en) 2007-06-20 2016-01-12 Milestone Pharmaceuticals Inc. Short acting phenylalkylamine calcium channel blockers and uses thereof
KR101052620B1 (ko) * 2008-08-28 2011-07-29 한국과학기술연구원 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물
ES2543470T3 (es) * 2009-09-30 2015-08-19 Microdose Therapeutx, Inc. Métodos y composiciones para el tratamiento del fenómeno de Raynaud
WO2015073919A1 (en) * 2013-11-14 2015-05-21 University Medical Pharmaceuticals Corporation Microneedles for therapeutic agent delivery with improved mechanical properties
DK3283067T3 (da) * 2015-04-14 2020-03-30 Milestone Pharmaceuticals Inc Meget vandopløselige salte af korttidsvirkende calciumkanalblokkere på basis af phenylalkylamin og anvendelser heraf
US20230065401A1 (en) * 2021-07-15 2023-03-02 Milestone Pharmaceuticals Inc. Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (de) * 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
US3957845A (en) * 1962-04-27 1976-05-18 Knoll A.G. Chemische Fabriken Trifluoromethyl-substituted phenyl acetonitriles
DE1493904A1 (de) * 1965-07-31 1969-06-19 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE2059923C3 (de) * 1970-12-05 1979-01-25 Knoll Ag, 6700 Ludwigshafen l-a-Isopropyl-o-[(N-methyl-N-homoveratryl)v-aminopropyl] -3,4-dimethoxyphenylacetonitril, Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel
JPS5118940B2 (pt) 1971-12-25 1976-06-14
DE2631222C3 (de) * 1976-07-12 1979-01-04 Knoll Ag, 6700 Ludwigshafen Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE3144150A1 (de) * 1981-04-10 1982-12-09 Basf Ag, 6700 Ludwigshafen (omega)-cyan-1,(omega)-diphenyl-azaalkan-derivate, ihre herstellung und diese enthaltende arzneimittel
DE3433383A1 (de) * 1984-09-12 1986-03-20 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phenyl-acetonitril-derivate
DE3603032A1 (de) * 1986-01-31 1987-08-06 Basf Ag Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel
US4833162A (en) * 1988-02-03 1989-05-23 American Cyanamid Company Substituted benzeneacetonitriles and their use as calcium channel blockers
PT96283A (pt) 1989-12-21 1991-09-30 Searle & Co Metodos de utilizacao de 2-isopropil-2-fenilaminovaleronitrilos como imunossupressores e vasodilatadores
US5486539A (en) * 1989-12-21 1996-01-23 G. D. Searle & Co. Method of using phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US5162569A (en) * 1989-12-21 1992-11-10 G. D. Searle & Co. Phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US5247119A (en) * 1990-12-12 1993-09-21 G. D. Searle & Co. Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5451604A (en) * 1993-07-26 1995-09-19 G. D. Searle & Co. Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives
US5910601A (en) * 1994-09-26 1999-06-08 Darwin Discovery Limited Chiral nitriles, their preparation and their use for the manufacture of verapamil and analogues
US5859279A (en) 1996-09-10 1999-01-12 Darwin Discovery Limited Compound and process
US6750238B1 (en) 2000-05-12 2004-06-15 The University Of Toledo Aralkyl ester soft drugs
US7511077B2 (en) * 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
GB2435824A (en) 2006-03-09 2007-09-12 Esteve Labor Dr Use of nitrile compounds in the treatment of food related and other disorders
CA2693627C (en) 2007-06-20 2016-01-12 Milestone Pharmaceuticals Inc. Short acting phenylalkylamine calcium channel blockers and uses thereof

Also Published As

Publication number Publication date
US20180280339A1 (en) 2018-10-04
CA2693627A1 (en) 2008-12-24
KR20100043175A (ko) 2010-04-28
BRPI0812919B8 (pt) 2021-05-25
US20140296335A1 (en) 2014-10-02
EP2170050B1 (en) 2014-06-18
US20210315855A1 (en) 2021-10-14
PT2170050E (pt) 2014-09-04
US20100190852A1 (en) 2010-07-29
US20160074354A1 (en) 2016-03-17
MX347325B (es) 2017-04-12
US20160374982A1 (en) 2016-12-29
PL2170050T3 (pl) 2014-12-31
JP2010530429A (ja) 2010-09-09
US20210059972A1 (en) 2021-03-04
US20170312243A1 (en) 2017-11-02
JP5421908B2 (ja) 2014-02-19
AU2008266798A1 (en) 2008-12-24
CA2693627C (en) 2016-01-12
US20170312242A1 (en) 2017-11-02
US10010523B2 (en) 2018-07-03
HK1140913A1 (en) 2010-10-29
BRPI0812919B1 (pt) 2019-01-29
HRP20140801T1 (hr) 2014-11-21
DK2170050T3 (da) 2014-09-29
MX2009014052A (es) 2010-03-01
WO2008156820A1 (en) 2008-12-24
CN101754678B (zh) 2014-04-16
US20220142963A1 (en) 2022-05-12
US20200230097A1 (en) 2020-07-23
US10010524B2 (en) 2018-07-03
US9463179B2 (en) 2016-10-11
EP2170050A4 (en) 2010-11-24
US10010522B2 (en) 2018-07-03
US20240115543A1 (en) 2024-04-11
NZ582033A (en) 2012-07-27
EP2170050A1 (en) 2010-04-07
US20190142781A1 (en) 2019-05-16
CN101754678A (zh) 2010-06-23
US20170312241A1 (en) 2017-11-02
ES2498047T3 (es) 2014-09-24
CY1115619T1 (el) 2017-01-04
US20230255923A1 (en) 2023-08-17
US20190380993A1 (en) 2019-12-19
SI2170050T1 (sl) 2014-12-31
KR101541557B1 (ko) 2015-08-03
US9227918B2 (en) 2016-01-05
US9737503B2 (en) 2017-08-22
AU2008266798B2 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
NO2022027I1 (no) Combination of daunorubicin and cytarabine
BRPI0815204A2 (pt) Dispositivo de administração fecal e utilização do dispositivo
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0813989A2 (pt) Dispositivo e método de retração de tecido gengival
BRPI0821424A2 (pt) curativo para tecido mucoso e método de uso
BR112012003661A2 (pt) "compostos de biarila e métodos de uso dos mesmos."
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0916269A2 (pt) dispositivo de modificação de tecido e seu método de uso
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI0813955A2 (pt) composições terapêuticas e o uso das mesmas
FI20060449A0 (fi) Mammografiamenetelmä ja mammografialaite
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
BRPI0816835A2 (pt) dispositivo de pulverização e método de uso do mesmo
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
FI20086253A0 (fi) Sieniendoglukanaasit, niiden valmistus ja käyttö
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
BRPI0914488A2 (pt) "composições de limpeza incluindo siloxanos de sorbitano modificados e uso das mesmas"
BRPI0918789A2 (pt) variantes de beta-glicosidase tendo atividade melhorada, e uso das mesmas
FI20086250A0 (fi) Sieniendoglukanaasit, niiden valmistus ja käyttö
BRPI0813355A2 (pt) Compostos de quinazolinona e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF